Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: PerkinElmer; Qiagen; Roche; and More

NEW YORK (GenomeWeb) – PerkinElmer this week declared a regular quarterly dividend of $.07 per share of common stock. The dividend is payable on Feb. 10, 2017 to all shareholders of record at the close of business on Jan. 20, 2017.

Qiagen announced this week that its shareholders have approved a previously announced proposal for a $250 million synthetic share repurchase plan. The plan combines a direct capital repayment with a reverse stock split. The transactions are expected to be completed in early January 2017 following the expiration of a two-month creditor objection period. The capital repayment is part of an initiative the company formed in July to return $300 million to shareholders by the end of 2017.

This week, Roche held a dedication ceremony at its Roche Diagnostics North American headquarters in Indianapolis. The city's mayor, Joe Hogsett, and Roche Chairman Christoph Franz both attended the celebration, which was held upon the completion of the first phase of the site's refurbishment. Roche announced plans in June 2012 to invest more than $300 million in the site over the next 10 years. The company has built five new buildings since then and has made upgrades to the existing buildings, including to IT infrastructure and manufacturing technology.

New England Biolabs said today that it has inked an agreement to supply German firm AmpTec with enzymes for in vitro transcription and capping of RNA. Based in Hamburg, AmpTec manufactures synthetic nucleic acid products for research, diagnostics, and therapeutics.

Cell Signaling Technology Europe business unit Bioké announced this week that it has signed a deal with Acea Biosciences to distribute Acea's NovoCyte Flow Cytometer in Belgium, the Netherlands, and Luxembourg.

NantHealth announced today that Horizon Blue Cross Blue Shield of New Jersey will cover its GPS Cancer test for members enrolled in investigational studies for key cancer types, such as non-small cell lung cancer, breast cancer, and colon cancer, at health systems in the mid-Atlantic. These institutions include the Hospital of University of Pennsylvania, Cancer Institute of New Jersey, Hackensack Medical Center, Meridian Hospital, and Regional Cancer Care Associates. GPS Cancer is a molecular test that integrates quantitative proteomics with whole-genome and transcriptome sequencing. 

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the GenomeWeb site.